The availability of BCL6‐specific inhibitors, associations with breast cancer patient tumor response to chemotherapy treatment including paclitaxel, and increased expression of BCL6 in MDA‐MB‐231 cells with acquired paclitaxel resistance provided further rationale for studying the role of BCL6 in paclitaxel response in breast cancer. Here, BCL6 is linked to breast carcinoma.